Byoung Chul

Featured in: Favicon

biomedcentral.com Favicon

aacrjournals.org (+2) Favicon

ascopubs.org Favicon

ascopost.com Favicon

biorxiv.org Favicon

onlinelibrary.wiley.com + 2 more

Articles

First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial | Journal of Clinical Oncology

2 months ago | brnw.ch | Byoung Chul Cho |Byoung Chul |Juan Li

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.
Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study | Journal of Clinical Oncology

Jan 6, 2025 | lifestyle-medicine.mednet.co.il | Byoung Chul Cho |Byoung Chul |Jacob Sands

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.
Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study | Journal of Clinical Oncology

Jan 6, 2025 | brnw.ch | Byoung Chul Cho |Byoung Chul |Jacob Sands

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.
EQ-CBM: A Probabilistic Concept Bottleneck with Energy-based Models and Quantized Vectors

Sep 22, 2024 | arxiv.org | Byoung Chul
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer | NEJM

Sep 13, 2024 | nejm.org | Byoung Chul Cho |Byoung Chul

Published September 13, 2024N Engl J Med 2024;391:1313-1327DOI: 10.1056/NEJMoa2404873 For permission requests, please contact NEJM Reprints at [email protected] NotesThis article was published on September 13, 2024, at NEJM.org. A data sharing statement provided by the authors is available with the full text of this article at NEJM.org. Supported by AstraZeneca. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
ctDNA dynamics and mechanisms of acquired resistance in patients treated with osimertinib with or without bevacizumab from the randomised phase II ETOP-BOOSTER trial

Sep 9, 2024 | aacrjournals.org | Byoung Chul Cho |Byoung Chul |Institut Català d'Oncologia |Hospitalet de Llobregat

Background: ETOP 10-16 BOOSTER study was a randomised phase II trial of osimertinib and bevacizumab versus osimertinib in patients with an acquired EGFR T790M mutation. The mechanisms of acquired resistance to osimertinib and bevacizumab have not been described previously. Methods: Next generation sequencing (Guardant360®) was conducted in serial plasma samples. The association between ctDNA and efficacy outcomes was explored and molecular alterations at progression were described.
Pre-Clinical Studies of a Novel Bispecific Fusion Protein Targeting C3b and VEGF in Neovascular and Nonexudative AMD Models

Jul 25, 2024 | paperity.org | Byoung Chul

Ophthalmology and Therapy, Jun 2024 KNP-301 is a bi-specific fragment crystallizable region (Fc) fusion protein, which inhibits both C3b and vascular endothelial growth factor (VEGF) simultaneously for patients with late-stage age-related macular degeneration (AMD). The present study evaluated in vitro potency, in vivo efficacy, intravitreal pharmacokinetics (IVT PK), and injectability of KNP-301.
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA | Clinical Cancer Research | American Association for Cancer R

Jul 20, 2023 | aacrjournals.org | Byoung Chul Cho |Byoung Chul |Chang Gung |Guangdong Academy

Plasma circulating tumor DNA (ctDNA) analysis is used for genotyping advanced non–small cell lung cancer (NSCLC); monitoring dynamic ctDNA changes may be used to predict outcomes. This was a retrospective, exploratory analysis of two phase III trials [AURA3 (NCT02151981), FLAURA (NCT02296125)]. All patients had EGFR mutation-positive (EGFRm; ex19del or L858R) advanced NSCLC; AURA3 also included T790M-positive NSCLC.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →